What is Sequence Bio?
Sequence Bio is a biotechnology firm dedicated to revolutionizing drug discovery. Leveraging a sophisticated systems biology approach, the company integrates multi-omics data with real-world patient information to construct custom discovery cohorts. This methodology is applied to both common and rare diseases, with the goal of accelerating research and development timelines through strategic collaborations with leading pharmaceutical and biotech entities. Based in Newfoundland and Labrador, Sequence Bio capitalizes on the founder effect to enhance the identification of impactful genetic variants, positioning itself at the forefront of precision medicine.
How much funding has Sequence Bio raised?
Sequence Bio has raised a total of $3.5M across 2 funding rounds:
Angel/Seed
$500K
Angel/Seed
$3M
Angel/Seed (2015): $500K, investors not publicly disclosed
Angel/Seed (2016): $3M led by Killick Capital, Klister Credit, and Data Collective
Key Investors in Sequence Bio
Killick Capital
Killick Capital is a leading private equity firm based in Atlantic Canada, focusing on partnering with local businesses and those in the aerospace sector. The firm aims to identify and fund investments that promise substantial growth and long-term value creation.
Klister Credit
Klister Credit Corp is a company that operates in the Banking industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in Toronto, Ontario, Canada.
Data Collective
Data Collective is a startup non-profit focused on building and supporting technology to help people find, understand, and share data, advancing the knowledge and education of citizens everywhere. They strive to be non-partisan and unbiased in their data initiatives.
What's next for Sequence Bio?
With the recent major strategic investment, Sequence Bio is poised to further enhance its discovery platforms and expand its collaborative efforts. The enterprise-level funding suggests a focus on scaling operations, advancing its pipeline of drug candidates, and potentially exploring new therapeutic areas. The company's commitment to utilizing advanced data analytics and biological insights indicates a strategic direction towards de-risking drug development and bringing novel treatments to patients more efficiently. Future growth will likely involve deepening partnerships with industry leaders and potentially pursuing further rounds of financing to support late-stage development and commercialization.
See full Sequence Bio company page
